Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs. Publisher statement: This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. © The biochemical society.
    Original languageEnglish
    Pages (from-to)377-400
    Number of pages34
    JournalClinical Science
    Volume126
    Issue number6
    DOIs
    Publication statusPublished - 1 Mar 2014

    Fingerprint

    MicroRNAs
    Biomarkers
    Wounds and Injuries
    Neoplasms
    Pharmaceutical Preparations
    Therapeutics
    Survival Rate
    Sensitivity and Specificity
    Messenger RNA
    Cardiotoxicity
    Research

    Bibliographical note

    The full text of this item is not available from the repository.
    This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. © The biochemical society.

    Keywords

    • biomarker
    • cancer-therapy-induced cardiotoxicity
    • early clinical assessment
    • microRNA
    • subclinical cardiac injury

    Cite this

    @article{23e885b3aca14d5abcb73952a839ae7e,
    title = "Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury",
    abstract = "Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs. Publisher statement: This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. {\circledC} The biochemical society.",
    keywords = "biomarker, cancer-therapy-induced cardiotoxicity, early clinical assessment, microRNA, subclinical cardiac injury",
    author = "Hardip Sandhu and Maddock, {Helen L.}",
    note = "The full text of this item is not available from the repository. This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. {\circledC} The biochemical society.",
    year = "2014",
    month = "3",
    day = "1",
    doi = "10.1042/CS20120620",
    language = "English",
    volume = "126",
    pages = "377--400",
    journal = "Clinical Science",
    issn = "0143-5221",
    publisher = "Portland Press",
    number = "6",

    }

    TY - JOUR

    T1 - Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury

    AU - Sandhu, Hardip

    AU - Maddock, Helen L.

    N1 - The full text of this item is not available from the repository. This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. © The biochemical society.

    PY - 2014/3/1

    Y1 - 2014/3/1

    N2 - Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs. Publisher statement: This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. © The biochemical society.

    AB - Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs. Publisher statement: This research was originally published in Clinical Science. Sandhu, H. and Maddock, H.L., Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science. 2014; 126(6): 377-400. © The biochemical society.

    KW - biomarker

    KW - cancer-therapy-induced cardiotoxicity

    KW - early clinical assessment

    KW - microRNA

    KW - subclinical cardiac injury

    U2 - 10.1042/CS20120620

    DO - 10.1042/CS20120620

    M3 - Article

    VL - 126

    SP - 377

    EP - 400

    JO - Clinical Science

    JF - Clinical Science

    SN - 0143-5221

    IS - 6

    ER -